Abstract
The study by Ying, et al1 of ischemic stroke risk in systemic sclerosis (SSc) reported increased prevalence (15.3 vs 12.2 per thousand in the control cohort) and delineated a series of likely predisposing comorbidities. There is an additional consideration, also amenable to risk adjustment: such events are also characteristic of the effect of antiphospholipid antibodies (aPL)2.